Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.37 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994633 | 0.94 | HDAC3 (0.36) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL994635 | 0.94 | HDAC3 (0.36) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL650963 | 0.87 | AGTR1 (0.34) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL650964 | 0.87 | AGTR1 (0.34) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL652641 | 0.86 | MME (0.37) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL652634 | 0.86 | MME (0.41) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL652640 | 0.86 | MME (0.37) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL652633 | 0.86 | MME (0.41) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL650982 | 0.86 | HDAC3 (0.38) | MMEMMEL1HDAC3HDAC4HDAC1 | |
| SCHEMBL650983 | 0.86 | HDAC3 (0.38) | MMEMMEL1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119634-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MME 13/4885MMEL1 695/4885HDAC3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.